Protocols

Ablynx grabs a €15M milestones payment from Merck KGaA; EyeGate surges on Valeant payout

→ Belgium’s Ablynx has teed up one of its Nanobodies for osteoarthritis for Merck KGaA. The German company accepted it and will now take it into the clinic, triggering a €15 million milestone payment.

→ JDRF says it will support ViaCyte’s work on a Type 1 diabetes program.

→ Shares of EyeGate Pharmaceuticals $EYEG jumped on the news that it has grabbed a development milestone from Valeant for its pact covering the EyeGate II Delivery System and EGP-437 combination product for post-operative ocular inflammation and pain in ocular surgery patients.


The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 29,000+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Biotech Primer Toronto 2018

Head of DMPK, Director
Magenta Therapeutics Cambridge, MA
Research Scientist - Disease Biology & Cellular Pharmacology
Recursion Pharmaceuticals Salt Lake City
Sr/Medical Director, Medical Affairs
A Rare Disease Biotech New Brunswick, NJ
VP, Pharmacovigilance
Aeglea BioTherapeutics Austin, TX
Process Scientist/Lead
Tmunity Therapeutics Philadelphia, PA

Visit Endpoints Careers ->